A Study of ABT-751 in Patients With Renal Cell Cancer
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how
long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will
receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before
starting the next cycle of drug.